Voloridge Investment Management LLC Reduces Holdings in Humana Inc. (NYSE:HUM)

Voloridge Investment Management LLC decreased its position in shares of Humana Inc. (NYSE:HUM) by 43.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 300,693 shares of the insurance provider’s stock after selling 227,146 shares during the period. Voloridge Investment Management LLC owned about 0.25% of Humana worth $76,289,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the 4th quarter worth $30,000. LFA Lugano Financial Advisors SA grew its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in Humana during the 4th quarter worth $33,000. Finally, Transce3nd LLC acquired a new position in Humana during the 4th quarter worth $38,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Oppenheimer raised their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Raymond James raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a report on Thursday, May 1st. JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $286.81.

Humana Trading Up 3.9%

Shares of NYSE:HUM opened at $247.16 on Tuesday. The company has a market cap of $29.83 billion, a PE ratio of 24.84, a P/E/G ratio of 2.05 and a beta of 0.49. The company’s 50-day moving average price is $262.90 and its 200 day moving average price is $269.48. Humana Inc. has a fifty-two week low of $212.45 and a fifty-two week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same period in the previous year, the firm earned $7.23 EPS. Humana’s revenue was up 8.4% on a year-over-year basis. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.43%. Humana’s dividend payout ratio (DPR) is 25.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.